Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm Revises Profit Forecast

NEW YORK, July 11 - Paradigm Genetics announced yesterday that it had revised its earnings projections for the fourth quarter of 2003 from $.05 to $.06 per share profit to between a loss of $.04 per share and a profit of $.01 cent per share. The original guidance was issued in a year-end conference call held in February.


Despite its lowering of projections for profitability, Paradigm now expects to have $13 to $15 million in cash and cash equivalents at the end of 2003, as opposed to the $7 to $9 million projected previously. This new figure includes the $2.5 million line of revolving credit that Paradigm gained as part of its $7.5 million debt financing deal with Silicon Valley Bank of Santa Clara, Calif.The financing deal was also announced yesterday, as reported here.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.